drugset
drugset / Trial / NCT02794428

Chemoprevention of Gastric Carcinogenesis

NCT02794428 ↗

Phase 2 Completed 91 enrolled Vanderbilt-Ingram Cancer Center Cancer Prevention Pharmaceuticals, Inc. · collabNational Cancer Institute (NCI) · collab
RandomizedSingle-groupDouble-blindPrevention

Summary

A clinical study of the efficacy of oral alpha-difluoromethylornithine (eflornithine or DFMO) in male and female subjects ages 30-60 with gastric premalignant lesions in two high risk regions of Latin America.

Timeline

Start
2016-09-19
Primary completion
2022-12-20
Completion
2024-07-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Eflornithine Small molecule 500 mg Oral

Indications

gastric cancer gastric intestinal metaplasia